Maintenance CC-486 Improves Survival for Older Patients With AML
December 10th 2019
Maintenance treatment with CC-486, an oral formulation of azacitidine, extended median overall survival by 9.9 months compared with placebo for older patients with acute myeloid leukemia in first remission.